Hyderabad, India – January 31, 2025
Key Financial Highlights (₹ in Million)
| Particulars | Q3 FY25 | Q2 FY25 | Q3 FY24 | 9M FY25 | 9M FY24 | FY24 (Audited) |
|---|---|---|---|---|---|---|
| Revenue from Operations | 15,614.46 | 15,761.72 | 14,414.72 | 46,264.44 | 41,343.57 | 56,248.55 |
| Other Income | 125.16 | 115.96 | 97.91 | 328.24 | 295.49 | 400.08 |
| Total Income | 15,739.62 | 15,877.68 | 14,512.63 | 46,592.68 | 41,639.06 | 56,648.63 |
| Total Expenses | 15,173.62 | 15,399.84 | 14,313.01 | 45,370.95 | 41,224.48 | 55,914.20 |
| Profit Before Tax (PBT) | 566.00 | 477.84 | 199.62 | 1,221.73 | 414.58 | 734.43 |
| Net Profit (PAT) | 458.70 | 386.99 | 137.05 | 989.13 | 320.16 | 655.77 |
| Basic EPS (₹) | 3.84 | 3.24 | 1.15 | 8.28 | 2.69 | 5.48 |
Segment-Wise Performance
- Retail Revenue: ₹15,338.87 Mn (Q3 FY25) vs. ₹14,218.00 Mn (Q3 FY24)
- Diagnostic Services Revenue: ₹274.67 Mn (Q3 FY25) vs. ₹196.03 Mn (Q3 FY24)
- Others: ₹0.92 Mn (Q3 FY25) vs. ₹0.69 Mn (Q3 FY24)
Corporate Updates
- IPO Utilization: ₹662.50 Mn remains unutilized and placed in fixed deposits.
- Merger Approval: National Company Law Tribunal (NCLT) approved the merger of MHS Pharmaceuticals Private Limited with MedPlus Health Services.
- Deferred Tax Assets: ₹33.59 Mn recognized due to an assessment of future profitability.
Management Commentary
G. Madhukar Reddy, Managing Director & CEO, stated:"We continue to maintain strong revenue growth and profitability, driven by our retail expansion and efficiency improvements. The diagnostic segment is recovering, and we are optimistic about further strengthening our market position."
Strategic Outlook
- Retail Network Expansion: Strengthening presence in key markets.
- Technology Integration: Enhancing operational efficiencies and customer experience.
- Diagnostics Growth: Focus on scaling the segment to improve margins.
MedPlus Health Services Limited (NSE: MEDPLUS | BSE: 543427) remains committed to delivering strong financial performance and value to its shareholders.